Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic and Certican in comparison to standard therapy with Myfortic and a calcineurin inhibitor (Sandimmun Optoral or Prograf) in stable renal transplant patients

Next Previous
Trial Profile

Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic and Certican in comparison to standard therapy with Myfortic and a calcineurin inhibitor (Sandimmun Optoral or Prograf) in stable renal transplant patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate sodium; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms APOLLO
  • Sponsors Novartis

Most Recent Events

  • 27 Aug 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
  • 27 Aug 2014 Protocol has been amended to change in the treatment arm with an additional drug addition to the regimen- coticosteroids.
  • 08 Sep 2013 Four-year results presented at the 16th Congress of the European Society for Organ Transplantation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top